Chewy vs. Coupang: Which Consumer Stock Is a Better Buy in 2026?

Chewy is presented as the preferred 2026 retail investment, trading at a 16.3x forward P/E versus Coupang's 75.8x, while both trade at 0.8x sales. Chewy generated FY2025 revenue of $12.6 billion (+6%) and consensus expects FY2026 sales to rise 7% to $13.5 billion, with net income increasing nearly 50% to $333 million; its Modern Animal acquisition expands its veterinary-clinic network toward 47 locations. Coupang grew FY2025 revenue 14% to $34.5 billion but faces a difficult 2026 from a distribution-center fire, a 33 million-account data incident, regulatory pressure, and expectations for a FY2026 net loss before a projected 2027 recovery.

Analysis

CHWY's valuation discount is warranted only if the clinic rollout becomes a capital-intensive adjacency rather than a retention engine. The key economic test is whether Modern Animal raises pharmacy, food and Autoship spend per household enough to offset clinic labor, leasehold and integration costs; with a thin consolidated margin base, even modest underutilization can delay the expected earnings step-up. Near term, the market is likely to reward evidence of cross-sell and mature-clinic contribution rather than location-count targets.

CPNG has the more asymmetric operating leverage if customer retention normalizes after its operational and privacy disruptions. At a similar sales multiple, the market is effectively assigning little value to a recovery in contribution margin from existing fulfillment density; however, that upside is contingent on compensation, litigation and compliance costs remaining bounded. Taiwan expansion should be viewed as an investment call option, not a near-term valuation support, because new-market logistics typically depress margins before density inflects.

The non-obvious read is that CHWY's forward earnings multiple is flattered by a large projected profit increase from a low-margin base, while CPNG's headline forward P/E is largely uninformative during a temporary earnings trough. A pair can therefore isolate execution: CHWY needs healthcare monetization to validate consensus, whereas CPNG needs customer and margin recovery. AMZN is a second-order beneficiary if CPNG's cloud dependence converts regulatory remediation and security spending into higher AWS workloads, but the revenue effect is immaterial to AMZN's consolidated estimates.

Key Decisions for Investors

• Initiate a 3-6 month long CPNG / short CHWY dollar-neutral pair only after CPNG reports stable active-customer retention and no upward revision to breach-related charges. Target 15-25% relative upside if CPNG's contribution margin recovers; exit if Korean regulatory actions or compensation reserves materially exceed disclosed expectations.
• Keep CHWY on an earnings watch rather than chase the multiple: buy only if management quantifies Modern Animal cross-sell, clinic-level margins and payback periods, and FY2026 EPS guidance is maintained. A guidance cut tied to vet labor, integration costs or pharmacy share loss would invalidate the margin-expansion thesis.
• For outright CHWY exposure, use defined-risk post-earnings calls rather than stock ahead of clinic integration disclosures; the upside depends on proof of incremental economics, while downside is meaningful if consensus earnings growth is deferred by even 1-2 quarters.
• Monitor CPNG's quarterly fulfillment/product-commerce contribution profit and WOW-member retention over the next two reports. A sequential improvement despite remediation costs is the catalyst for rerating; continued customer attrition makes the low sales multiple a value trap.